RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Immunovia AB (publ) ROCE 2024

Immunovia AB (publ) ROCE

-4.43

Immunovia AB (publ) Dividend yield

Ticker

IMMNOV.ST

ISIN

SE0006091997

WKN

A2AG0F

In 2024, Immunovia AB (publ)'s return on capital employed (ROCE) was -4.43, a 464.56% increase from the -0.78 ROCE in the previous year.

Immunovia AB (publ) Aktienanalyse

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a leading company in cancer diagnostics based in Lund, Sweden. Founded in 2007 by a group of scientists and entrepreneurs, the company specializes in the development, production, and marketing of diagnostic tests. Immunovia aims to develop innovative and reliable methods for early cancer detection to improve the progress and quality of life for cancer patients. The company's business model is based on research and development of state-of-the-art diagnostic tests, which are distributed worldwide through a network of partners. Immunovia collaborates closely with academic institutions, medical centers, and hospitals to promote research activities and conduct clinical studies. The company's goal is to develop biomarker-based tests for early cancer detection to increase patient survival rates. Immunovia operates in various fields, including pancreatic cancer diagnosis, colorectal cancer diagnosis, lupus diagnosis, and general cancer diagnostics. The company has developed products based on its diagnostic tests, such as the IMMray™ PanCan-d Test for pancreatic cancer diagnosis, IMMray™ Colon Test for colorectal cancer diagnosis, IMMray™ Lupus Test for lupus diagnosis, and IMMray™ Cancer-Screening Test for general cancer diagnostics. Immunovia actively collaborates with various partners, including strategic partnerships with leading biotechnology and pharmaceutical actors, to develop advanced diagnostic products. The company also has a strong financial base to fund its research activities and clinical studies. Overall, Immunovia is dedicated to developing innovative diagnostic tests for early cancer detection and is considered one of the leading players in the cancer diagnostics industry. Immunovia AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Immunovia AB (publ)'s Return on Capital Employed (ROCE)

Immunovia AB (publ)'s Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Immunovia AB (publ)'s ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Immunovia AB (publ)'s ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Immunovia AB (publ)’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Immunovia AB (publ) Stock

What is the ROCE (Return on Capital Employed) of Immunovia AB (publ) this year?

The ROCE of Immunovia AB (publ) is -4.43 undefined this year.

How has the ROCE (Return on Capital Employed) of Immunovia AB (publ) developed compared to the previous year?

The ROCE of Immunovia AB (publ) has increased by 464.56% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Immunovia AB (publ)?

A high Return on Capital Employed (ROCE) indicates that Immunovia AB (publ) has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Immunovia AB (publ)?

A low ROCE (Return on Capital Employed) can indicate that Immunovia AB (publ) has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Immunovia AB (publ) impact the company?

An increase in the ROCE of Immunovia AB (publ) can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Immunovia AB (publ) affect the company?

A decrease in ROCE of Immunovia AB (publ) can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Immunovia AB (publ)?

Some factors that can affect Immunovia AB (publ)'s ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Immunovia AB (publ) so important for investors?

The ROCE of Immunovia AB (publ) is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Immunovia AB (publ) take to improve the ROCE?

To improve the ROCE, Immunovia AB (publ) can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Immunovia AB (publ) pay?

Over the past 12 months, Immunovia AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovia AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Immunovia AB (publ)?

The current dividend yield of Immunovia AB (publ) is .

When does Immunovia AB (publ) pay dividends?

Immunovia AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunovia AB (publ)?

Immunovia AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Immunovia AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunovia AB (publ) located?

Immunovia AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunovia AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunovia AB (publ) from 5/30/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Immunovia AB (publ) pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Immunovia AB (publ) in the year 2023?

In the year 2023, Immunovia AB (publ) distributed 0 SEK as dividends.

In which currency does Immunovia AB (publ) pay out the dividend?

The dividends of Immunovia AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunovia AB (publ)

Our stock analysis for Immunovia AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovia AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.